Rick E Winningham
Chairman and Chief Executive Officer
Rick E Winningham joined Theravance as Chief Executive Officer and a member of the Board of Directors in October 2001, and was appointed Chairman of the Board of Directors in April 2010.
Since becoming CEO in late 2001, Theravance
has successfully transitioned from a private research-based small molecule discovery company to a public company with a robust portfolio of product candidates.
From 1997 to 2001 he served as President, Bristol-Myers Squibb (BMS) Oncology/Immunology/Oncology Therapeutics Network (OTN) and also as President of Global Marketing from 2000 to 2001.
In addition to operating responsibility for U.S. Oncology/Immunology/OTN, Mr. Winningham
also had full responsibility for Global Marketing
in the Cardiovascular, Infectious Disease, Immunology, Oncology/Metabolics and GU/GI/Neuroscience therapeutic areas.
Over a fifteen-year period with BMS and its predecessor, Bristol-Myers, Mr. Winningham held various U.S. and global management positions.
tenure with BMS
was associated with the development and commercialization of several major pharmaceutical products, such as Taxol®, Paraplatin®, Zerit®, Videx®, Reyataz®, and Abilify®.
Mr. Winningham holds an M.B.A. from Texas Christian University and a B.S. from Southern Illinois University.
He is a member of the Board of Directors of California Healthcare Institute (CHI) and Jazz Pharmaceuticals, Inc.
Mr. Winningham is also a member of the External Advisory Board for the College of Business and Administration and Business Hall of Fame at Southern Illinois University.